Patents Examined by Thomas D. Mays
-
Patent number: 4980288Abstract: Cloned DNA is mutated by creating a single-stranded target region in a cloned DNA segment, and introducing a mutation into the single-stranded target region by treating the target region with a chemical or biological mutagenizing agent capable of introducing mutations into single-stranded DNA. The mutated target region then is rendered double-stranded and a microorganism is transformed with the mutated double-stranded DNA present in an expression vector. The transformed microorganism is cultivated under conditions wherein the mutated DNA is expressed to form an expression product, and the expression product is screened to identify a desired mutation in the DNA segment. Mutant subtilisins of enhanced thermal stability are also disclosed.Type: GrantFiled: December 14, 1987Date of Patent: December 25, 1990Assignee: Genex CorporationInventors: Philip N. Bryan, Michele L. Rollence, Michael W. Pantoliano
-
Patent number: 4977247Abstract: Immobilized IgG binding proteins and the use thereof to effect affinity chromatography and separate the subclasses of IgG. Disclosed are cysteine-containing IgG binding proteins which have high binding capacity for human IgG and mouse monoclonal IgG.Type: GrantFiled: May 19, 1989Date of Patent: December 11, 1990Assignee: Genex CorporationInventors: Stephen R. Fahnestock, Timothy Lee, Marie H. Wroble
-
Patent number: 4975374Abstract: The invention relates to a mutant glutamine synthetase (GS) enzyme which is resistant to inhibition by herbicidal GS inhibitors, such as phosphinothricin (PPT), genetic sequences coding therefor, plants cells and prokaryotes transformed with the genetic sequences, and herbicidal GS inhibitor-resistant plant cells and plants.Type: GrantFiled: February 4, 1987Date of Patent: December 4, 1990Assignee: The General Hospital CorporationInventors: Howard Goodman, Shiladitya DasSarma, Edmund Tischer, Theresa K. Peterman
-
Patent number: 4970296Abstract: Disclosed is a heterodimeric T lymphocyte receptor comprising an alpha and a beta subunit. Each subunit consists of a signal peptide, variable, joining, constant, transmembrane, and cytoplasmic regions. The two subunits are connected by a disulfide bond between cysteine residues located between the constant and transmembrane region.The structure, amino acid, and nucleotide sequence of the lymphocyte receptor were determined using CDNA clones derived from a functional murine cytotoxic T lymphocyte clone. The genes corresponding to these cDNA are expressed and rearranged specifically in T cells and have significant sequence homologies to immunoglobulin V and C genes.Both the T cell receptor protein and its subunits may be produced from the cDNA clones. The protein molecules may be further used for the production of T-cell clone specific antibodies.Type: GrantFiled: July 27, 1989Date of Patent: November 13, 1990Assignees: Massachusetts Institute of Technology, Board of Trustees of Leland Stanford Jr. UniversityInventors: Haruo Saito, David M. Kranz, Herman N. Eisen, Susumu Tonegawa
-
Patent number: 4968626Abstract: Genomic and cDNA sequences coding for a protein having substantially the same biological activity as human protein C are disclosed. Recombinant plasmids and bacteriophage transfer vectors incorporating these sequences are also disclosed.Type: GrantFiled: August 15, 1985Date of Patent: November 6, 1990Assignee: Board of Reagents of the University of WashingtonInventors: Donald C. Foster, Earl W. Davie
-
Patent number: 4966849Abstract: DNA sequences encoding a protein having angiogenic activity and mutated DNA sequences encoding a protein having decreased angiogenic activity are disclosed. Expression vectors containing these wild-type or mutated sequences are introduced into host cells and direct the production of wild-type or mutant angiogenic proteins. Proteins produced according to the invention are useful in the diagnosis of malignancies, for promoting wound healing, and for other diagnostic and therapeutic purposes. Mutant proteins produced according to the invention are useful therapeutic compositions as angiogensis inhibitors, which may retard tumor growth by inhibiting the development of a hemovascular network.Type: GrantFiled: February 2, 1989Date of Patent: October 30, 1990Assignee: President and Fellows of Harvard CollegeInventors: Bert L. Vallee, Kotoku Kurachi
-
Patent number: 4965197Abstract: A coryneform expression and secretion system for homologous and heterologous genes consisting of the host, nucleotide sequences encoding a protein of interest, signals for expression and, optionally, targeting signals which direct membrane anchoring and for secretion and processing of the expressed protein. Regulatory signals may be utilized to control the rate and extent of expression and secretion. The system may further include compounds such as ionophores for altering the membrane transport of the host. The host itself may be mutated to alter transport, for example, by decreasing the mycolic acid content of Corynebacteria species.The preferred host is a Corynebacterium although other coryneforms deficient in extracellular protease production may also be used. C. glutamicum is used as a model organism for the secretion system.Type: GrantFiled: December 5, 1989Date of Patent: October 23, 1990Assignee: Massachusetts Institute of TechnologyInventors: Wolfgang Liebl, Anthony J. Sinskey
-
Patent number: 4963487Abstract: Disclosed is a method and linear DNA fragments for use in the deletion of a gene from a bacteria with a single step procedure that is applicable to any essential or nonessential gene which has been cloned. Chromosomal deletions are constructed by transformation of a cell strain with linear DNA fragments containing a locus for resistance to an antibiotic, or any other gene allowing for rapid phenotypic selection, flanked by sequences homologous to closely spaced regions on the cell chromosome on either side of the gene to be deleted, in combination with the immediate subsequent deletion or inactivation of the recA gene. By selecting for a double-crossover event between the homologous sequences, shown by the antibiotic resistance or other detectable phenotype, a chromosome disruption can be selected for which has effectively deleted an entire gene.Type: GrantFiled: September 14, 1987Date of Patent: October 16, 1990Assignee: Massachusetts Institute of TechnologyInventor: Paul R. Schimmel
-
Patent number: 4960704Abstract: A modified hygromycin B resistance-conferring gene either alone or in translational reading phase with a gene or portion of a gene is disclosed. The invention further comprises recombinant DNA cloning vectors and transformants of the aforementioned DNA.Type: GrantFiled: May 31, 1988Date of Patent: October 2, 1990Assignee: Eli Lilly and CompanyInventors: Thomas D. Ingolia, Kevin R. Kaster, R. Nagaraja Rao
-
Patent number: 4959318Abstract: Genomic and cDNA sequences coding for a protein having substantially the same biological activity as human protein C and recombinant transfer vectors comprising these sequences are disclosed.Methods are disclosed for producing a protein which has substantially the same biological activity as human protein C. The protein, which may be in the form of activated protein C, is produced by mammalian host cells transfected with a plasmid capable of integration in mammalian host cell DNA. The plasmid includes a promoter followed downstream by a nucleotide sequence which encodes a protein having substantially the same structure and/or activity as human protein C, the nucleotide sequence being followed downstream by a polyadenylation signal.Type: GrantFiled: October 29, 1986Date of Patent: September 25, 1990Assignee: ZymoGenetics, Inc.Inventors: Donald C. Foster, Mark J. Murray, Kathleen L. Berkner
-
Patent number: 4957869Abstract: Disclosed are peptides comprising the amino acidsAsp-Arg-Ala-X-Gly-Gln-Pro-Ala-Glywherein X represents Asp or Ala, said peptides eleciting antibodies against the P. vivax circumsporozoite protein. Also disclosed are DNA sequences coding for such peptides.Type: GrantFiled: April 5, 1988Date of Patent: September 18, 1990Assignee: New York UniversityInventors: David E. Arnot, Vincenzo Enea, Ruth S. Nussenzweig, Victor N. Nussenzweig
-
Patent number: 4956296Abstract: A cloned gene encoding Protein G, or functionally active portions thereof, vectors containing the cloned gene, and microorganisms transformed by those vectors are disclosed.Type: GrantFiled: June 20, 1988Date of Patent: September 11, 1990Assignee: Genex CorporationInventor: Stephen R. Fahnestock
-
Patent number: 4954618Abstract: A cloned gene encoding Protein G, or functionally active portions thereof, vectors containing the cloned gene, and microorganisms transformed by those vectors are disclosed.Type: GrantFiled: March 15, 1989Date of Patent: September 4, 1990Assignee: Genex CorporationInventor: Stephen R. Fahnestock
-
Patent number: 4952682Abstract: A novel highly effective prokaryotic expression system is exemplified specifically by being used to produce the useful enzyme .beta.-glucuronidase (BG). This system uses a hybrid plasmid comprising BG gene promoter DNA. The level of expression of BG by an E. coli K-12 derivative host is in the 50% of total cellular protein range. The invention expression system also can be used to express other useful proteins, as disclosed herein.Type: GrantFiled: September 30, 1988Date of Patent: August 28, 1990Assignee: Repligen CorporationInventors: Algis Anilionis, John L. Palmer
-
Patent number: 4950603Abstract: DNA compounds encoding the Streptomyces lipmanii isopenicillin N synthetase (IPNS) gene are useful for constructing a variety of recombinant DNA vectors. The vectors are useful in producing IPNS in a wide variety of host cells, such as Streptomyces, Penicillium, and Cephalosporium. DNA compounds encoding the transcription and translation activating sequence and transcription termination sequence of the S. lipmanii IPNS gene are also useful in the construction of expression vectors, especially Streptomyces expression vectors. The S. lipmanii IPNS gene can be isolated from plasmid pOGO239, available from the Northern Regional Research Center under accession number NRRL B-18250.Type: GrantFiled: November 2, 1987Date of Patent: August 21, 1990Assignee: Eli Lilly and CompanyInventors: Thomas D. Ingolia, Barbara J. Weigel
-
Patent number: 4946786Abstract: 1Method for production of a composition consisting essentially of a T7-type DNA polymerase and thioredoxin. The method includes culturing a cell containing plasmid DNA encoding a T7-type DNA polymerase to express the T7-type DNA polymerase from the plasmid DNA, and purifying the T7-type DNA polymerase expressed from the cell to reduce the exonuclease activity associated with the T7-type DNA polymerase compared to the level of exonuclease activity associated with a corresponding naturally-occurring T7-type DNA polymerase.Type: GrantFiled: March 1, 1990Date of Patent: August 7, 1990Assignee: President and Fellows of Harvard CollegeInventors: Stanley Tabor, Charles C. Richardson
-
Patent number: 4942130Type: GrantFiled: December 14, 1987Date of Patent: July 17, 1990Assignee: President & Fellows of Harvard CollegeInventors: Stanley Tabor, Charles C. Richardson
-
Patent number: 4929559Abstract: One of the E. coli strains of the Clarke and Carbon collection [Cell, 9, 91-99] has been found to contain a plasmid which we have isolated and termed pLC3-13, which contains genetic information coding for prolipoprotein signal peptidase. A 4.3 kb fragment containing this genetic information has been prepared, other plasmids have been prepared containing at least this fragment and strains of E. coli have been transformed thereby.Type: GrantFiled: February 23, 1988Date of Patent: May 29, 1990Assignee: Sankyo Company LimitedInventors: Shoji Mizushima, Hideo Yamagata
-
Patent number: 4923799Abstract: The invention provides a nucleic acid having a sequence which encodes a polypeptide that is at least part of a T cell antigen receptor. This encoded sequence is about 936 nucleotides in length and preferably is a human T cell antigen receptor. The nucleic acid sequence of one embodiment of the invention is shown in FIG. 3.The nucleic acid sequence may be used as a probe to determine whether an unknown cell, e.g., a tumor cell, is a T cell.Polypeptides encoded by the nucleic acid sequence include about 312 amino acids and are at least part of a T cell antigen receptor. They include at least one sequence which over 21 contiguous amino acids has greater than about 35% homology with mouse and human immunoglobin .lambda. light chains.Antibody to the polypeptide may be prepared and used to identify T cell antigen receptor and to determine whether an unknown cell, e.g., a tumor cell, is a T cell.Type: GrantFiled: November 9, 1987Date of Patent: May 8, 1990Assignee: The Ontario Cancer InstituteInventor: Tak W. Mak
-
Patent number: 4921794Abstract: This invention relates to T7-type DNA polymerases and methods for amplification of DNA, for example by polymerase chain reaction.Type: GrantFiled: December 5, 1988Date of Patent: May 1, 1990Assignee: President and Fellows of Harvard CollegeInventors: Stanley Tabor, Charles C. Richardson